In summary, the active components of ACP for the treatment of colon cancer include quercetin, emodin, kaempferol, and aloeemodin, and the effective targets include CASP3, CDK2, GSK3B, PIK3R1, HSP90AA1, MMP9, TOP2A, CCNB1, and MYC, with pathways in cancer, cell cycle, cellular senescence, the PI3K-Akt signaling pathway and the p53 signaling pathway, which contribute to multiple bioprocesses, such as drug response, signal transduction, angiogenesis, cell migration, apoptosis, and cell cycle. This evidence concerns the gene MYC and malignant colon neoplasm.